Business Description
Alterity Therapeutics Limited is an Australian medical research company focused on developing treatments for serious brain diseases such as Parkinson's disease and Multiple System Atrophy. Its lead treatment, ATH434, is currently being tested in multiple Phase II clinical trials targeting both conditions. The company also runs a drug discovery program that creates new chemical compounds aimed at addressing the root causes of neurological diseases. Founded in 1997 and headquartered in Melbourne, it was previously known as Prana Biotechnology Limited before adopting its current name in 2019.
